Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jade Ghosn

Showing results (241-250 of 267) with videos related to

Pageof 27
Sort By:
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 14, 2025
Quasi-species prevalence and clinical impact of evolving SARS-CoV-2 lineages in European COVID-19 cohorts, January 2020 to February 2022Matilda Berkell, Anna Górska, Mathias Smet, et al.
Nature Communications|February 10, 2026
Latent transition analysis for longitudinal studies of post-acute infection syndromesRoy Gusinow, Anna Górska, Lorenzo Maria Canziani, et al.
The Lancet. Infectious Diseases|October 13, 2011
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, , Dominique Costagliola, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2026
Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2Michelle Møhlenberg, Sofie Eg Jørgensen, Renée Marije van der Sluis, et al.
International Journal of Epidemiology|April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Charlotte Lewden, Vincent Bouteloup, et al.
The New England Journal of Medicine|December 8, 2022
Breakthrough Infections after Postexposure Vaccination against MpoxMichael Thy, Nathan Peiffer-Smadja, Morgane Mailhe, et al.
Plos One|October 12, 2012
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP studyEnrique Casalino, Bruno Bernot, Olivier Bouchaud, et al.
The Oncologist|December 15, 2025
Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre studyAndréa Clément de Givry, Pauline Manchon, Marianne Veyri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.
Virology Journal|April 25, 2025
SARS-CoV-2 lineage-dependent temporal phylogenetic distribution and viral load in immunocompromised and immunocompetent individualsKaren Zafilaza, Antoine Fauchois, Valentin Leducq, et al.
Pageof 27

Showing results (241-250 of 267) with videos related to

Sort By:
Pageof 27
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|March 14, 2025
Quasi-species prevalence and clinical impact of evolving SARS-CoV-2 lineages in European COVID-19 cohorts, January 2020 to February 2022Matilda Berkell, Anna Górska, Mathias Smet, et al.
Nature Communications|February 10, 2026
Latent transition analysis for longitudinal studies of post-acute infection syndromesRoy Gusinow, Anna Górska, Lorenzo Maria Canziani, et al.
The Lancet. Infectious Diseases|October 13, 2011
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study, , Dominique Costagliola, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2026
Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2Michelle Møhlenberg, Sofie Eg Jørgensen, Renée Marije van der Sluis, et al.
International Journal of Epidemiology|April 12, 2012
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration, Charlotte Lewden, Vincent Bouteloup, et al.
The New England Journal of Medicine|December 8, 2022
Breakthrough Infections after Postexposure Vaccination against MpoxMichael Thy, Nathan Peiffer-Smadja, Morgane Mailhe, et al.
Plos One|October 12, 2012
Twelve months of routine HIV screening in 6 emergency departments in the Paris area: results from the ANRS URDEP studyEnrique Casalino, Bruno Bernot, Olivier Bouchaud, et al.
The Oncologist|December 15, 2025
Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre studyAndréa Clément de Givry, Pauline Manchon, Marianne Veyri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2011
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe, , Fumiyo Nakagawa, et al.
Virology Journal|April 25, 2025
SARS-CoV-2 lineage-dependent temporal phylogenetic distribution and viral load in immunocompromised and immunocompetent individualsKaren Zafilaza, Antoine Fauchois, Valentin Leducq, et al.
Pageof 27